Navigation Links
Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
Date:9/9/2008

Clinical Trial Programs Funded Through 2009

SAN FRANCISCO, Sept. 9 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biopharmaceutical company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced the closing of a financing transaction with gross proceeds of $8.3 million USD, exceeding the target of $8 million USD. The offering was completed without the services of an agent.

The net proceeds of the private placement will be used to advance the Company's clinical development programs, including lead product JX-594, which is currently being evaluated in a randomized Phase II clinical trial for liver cancer. This is one of three clinical trials currently under way, which also include a Phase II trial for colon cancer and a Phase I trial targeting lung cancer and other solid tumors. Proceeds from the financing will also be used for research and development, general corporate purposes and to augment working capital.

"We are extremely pleased by the enthusiastic support of existing shareholders, and we welcome several new shareholders to the Company," said David H. Kirn, M.D., President and CEO of Jennerex. "This funding is expected to cover operations for the next 18 months, through the end of 2009, and specifically to fund the company through significant value inflection points, including completion of the above-mentioned clinical trials," said Dr. Kirn.

Jennerex also announces the appointment of Calvin Stiller, CM, O. ONT, MD, F.R.C.P. (C) to the Company's Board of Directors. Dr. Stiller is Chairman of the board and Chief Executive Officer of Stilco Corporation and BioQuest Innovations Inc. Dr. Stiller has also served as a director of NPS Pharmaceuticals Inc. since December 1999; and had served on the board of Allelix since April 1999 until its acquisition by NPS. From 1996 to 2005, Dr. Stiller served as Chairman and Chief Executive Offi
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
3. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
4. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
5. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
6. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
7. Renowned NJ-Based Video Assisted Thoracic Surgery (VATS) Team Completes 5,000th Successful Procedure
8. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
9. Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
10. NuVasive Completes Acquisition of Osteocel Biologics Business
11. Hologic Completes Cash Tender Offer for Third Wave Technologies, Inc.

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... , BOSTON, Nov. 25 Biotech fi...us, genomic data from the 1918 pandemic through th...t H1N1 pandemic, today issued its latest biochemic...the lethality of the H1N1 ("Swine Flu") virus has ... virus,s current outbreak in the spring of 2009 to...
(Date:11/25/2009)... , NEW YORK, Nov. 25 Reportli...rt is available in its catalogue: ,, Brazil Bi..., http://www.reportlinker.com/p0165503/Brazil-B...ml ,, Brazil Bioethanol Market Analysis and Fo...rovides detailed analysis and forecasts of the glo...
(Date:11/24/2009)... The New York investment bank KTA C...U) has agreed an AU$6.7 mil convertible note priva...he private placement was arranged by KTA Capital a... , New York (PRWEB) Novemb... bank KTA Capital, LLC ("KTA Capital") h...
(Date:11/24/2009)... Health care employment grew by 2...nly one to show consistent growth during the U.S. ...s remain in trouble, and health systems are coming...l, instead of just administrators. , ...re employment continued growing in October despite...
Breaking Biology Technology:Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 10KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4
... DIEGO, Jan. 26 Gen-Probe Incorporated,(Nasdaq: ...ase its fourth,quarter and full year 2008 financia...mately 4:00 p.m. Eastern Time (ET). The announceme....m. ET. Hank Nordhoff, chairman and chief,executiv...t, finance, and,chief financial officer, will host...
...ELES, Jan. 26 De Novo Software(TM), a leading pro...nnounced today an agreement with BD Biosciences to...xpress(TM) -- to customers in clinical, research a...s, a segment of BD (Becton, Dickinson and Company)... and reagents. , , "We look forward to providing ...
... Calif., Jan. 26 AMDL, Inc. (NYSE Alternext US: A...tical company with operations in the U.S. and Chin...y financial guidance and first quarter business ob... AMDL reaffirms its fiscal year 2008 financial gui...d range of US$32 million to $36 million, which rep...
Other Biology Technology:Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2008 Earnings Conference Call 2BD Biosciences to Distribute FCS Express 2AMDL, Inc. Announces 2009 Financial Guidance and First Quarter Business Objectives 2AMDL, Inc. Announces 2009 Financial Guidance and First Quarter Business Objectives 3AMDL, Inc. Announces 2009 Financial Guidance and First Quarter Business Objectives 4AMDL, Inc. Announces 2009 Financial Guidance and First Quarter Business Objectives 5AMDL, Inc. Announces 2009 Financial Guidance and First Quarter Business Objectives 6
(Date:11/24/2009)...search on bacterial communities throughout six lar...poral patterns, suggesting that scientists could u...mate change in the polar regions. The study, publi... Academy of Sciences Early Edition, shows that ba...hronously over time, correlating with seasonal shi...
(Date:11/23/2009)... strain of the deadly superbug MRSAan infection-ca...sposes a far greater health threat than previously...ding to a study in the December issue of Emerging...ly picked up in fitness centers, schools, and othe...en of MRSA within hospitals, the report found. , ...
(Date:11/23/2009)... Society says that western lowland gorillas living...the "mother lode" of more than 125,000 gorillas di...ened by growing humans activity in the region. , ...sts adjacent to the southwest border of Lac Tl Com... high densities of the great apes still exist in t...
Breaking Biology News(10 mins):Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2New study finds MRSA on the rise in hospital outpatients 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Tanning Beds as Harmful as Tanning in the Sun Reports Harvard Women 26apos 3Bs Health Watch 56061 1Tanning Beds as Harmful as Tanning in the Sun Reports Harvard Women 26apos 3Bs Health Watch 56061 2Implanet Using IBM Software to Protect Patients in the Event of Medical Device Recalls 56057 1Implanet Using IBM Software to Protect Patients in the Event of Medical Device Recalls 56057 2Implanet Using IBM Software to Protect Patients in the Event of Medical Device Recalls 56057 3Lead Levels in Many Lipsticks Higher Than Reported 56053 1Lead Levels in Many Lipsticks Higher Than Reported 56053 2Lead Levels in Many Lipsticks Higher Than Reported 56053 3
...yone who studied a little genetics in high school ...e the A,T,G and C that make up the DNA code. But ...tics in the past decade has drawn attention to a f...etimes replaces cytosine in the famous DNA double ...ow there,s a sixth. In experiments to be publishe...
...rkeley -- Move over, Y chromosome it,s time X got...y of the chromosome associated with being female, ...s Bachtrog and her colleagues show that the histor...as the much-studied, male-determining Y chromosome...nefits of sexual reproduction. , "Contrary to the...
...T. PAUL, Minn. A first of its kind study examinin...ncy has found the drug appears to cause abnormal b...ished in the April 15, 2009, online issue of Neur...y of Neurology. , "Methamphetamine use is an in...leading to an increasing number of children with p...
Other Biology News:New nucleotide could revolutionize epigenetics 2New nucleotide could revolutionize epigenetics 3New nucleotide could revolutionize epigenetics 4The story of X -- evolution of a sex chromosome 2The story of X -- evolution of a sex chromosome 3The story of X -- evolution of a sex chromosome 4Prenatal meth exposure linked to abnormal brain development 2
VZV IgM ELISA Kit, Single from Bio-Quant Inc.
...tom siRNA service provides the premium quality siR...tom siRNAs can be readily ordered online by provid...roviding the sense and antisense siRNA sequences. ...lencer Pre-designed siRNAs, which are already desi...
Bovine Serum Albumin from Equitech-Bio
Rabbit Anti-MPV17 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Biology Products: